View Report Details Global Migraine Market Report ----------------------------------------2016
View Report Details Executive Summary
Migraine is a common neurovascular disorder that is characterized by throbbing headaches and is commonly associated with other neurological symptoms, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraines are thought to result from the activation and sensitization of sensory neurons that have nerve endings in meningeal blood vessels. Migraines can be episodic or chronic. Chronic Migraine (CM) and Episodic Migraine (EM) are both part of the spectrum of migraine disorders, but are distinct clinical entities. The onset of migraine is preceded by certain triggers, which can be unique for each migraine sufferer.
Triptans and Ergots are among the most common drug options existing in the treatment market for migraine. The global migraine treatment market currently faces several unmet needs and is saturated with the availability of generic drugs. Several branded drugs are under development with safer and more effective profiles, given the vast opportunities existing in the market. The focus of upcoming drugs is to either cure migraine or to reduce the frequency to a level where patients can find tolerable relief.
The migraine market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing female population and rising awareness among physicians and patients. The major growth drivers of the migraine market includes rising spending on medicines, growing female population, increasing cigarette consumption and healthcare expenditure. However, the growth of the market will also remain challenged by complications associated with Triptans, treatment limitations for patients with CV (Cardio Vascular) risk and increased preference for OTC (Over the Counter) medications.
The report, “Global Migraine Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific market of the U.S. is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.
Among several drug options existing in the market, Triptans and Ergots are the most common treatment options available for migraine… Global Migraine Drug Market by Value (2013-2020E) The overall market for migraine drug is estimated to have reached US$.. billion in the year 2015, increasing from US$.. billion in year 2013. The drug market for migraine is further expected to reach US$.. billion and US$.. billion in year 2017 and 2020 respectively.
n ilo B $ S U
Nearly, …% of the global migraine treatment market is estimated to have been made up of medications based on active substance called Triptans in year 2015. The second group which accounted for nearly …% comprises medications based on Dihydroergotamine (DHE). In 2015, nearly ..% share of the therapeutic Botulinum toxin market represented treatment of chronic migraine followed by cervical dystonia and overactive bladder holding …% and …% share respectively. 2013
2015E
2017E
2020E
Global Migraine Drug Market by Category (2015E)
Triptans
DHE
Other
Global Therapeutic Botulinum Toxin Market by Indication (2015)
Chronic Migraine Overactive Bladder Axillary Hyperhidosis Achalasia Other Therapeutic Indications
Cervical Dystonia Spasticity Blepharospasm Other Movement Disorders
The driving forces for growth of Migraine market includes several innovations in medication delivery, increased level of awareness of migraine among doctors and patients combined with innovation in delivery of clinically proven marketed medications… The U.S. Total Migraine Population (2015-2022E) The U.S. migraine population is expected to reach … million by the end of year 2022, increasing from … million in 2015, on account of rising awareness among patients & physicians and increasing migraine prevalence.
n ilo M
Of .. million migraine population in the U.S., nearly .. million (..%) cases got diagnosed followed by nearly .. million (..%) undiagnosed cases. Out of the … million diagnosed cases, nearly … million (..%) cases were for prevention, while rest .. million (..%) cases were not for prevention. Of the total candidates for prevention therapy in the U.S. in year 2015, nearly ..% of the candidates were treated by neurologists. However, nearly ..% of the prevention candidates got primary care treatment for the given year. 2015
2016E
2017E
2018E
2019E
2020E
2021E
2022E
The U.S. Migraine Population by Diagnosis (2015E)
Undiagnosed Population
Candidates for Prevention
Not Candidates for Prevention
The U.S. Preventive Migraine Treatment by Specialty (2015)
Neurologists
Primary Care
Other Specialty
The U.S. migraine treatment market currently faces several unmet needs. The current treatment patterns necessitate introduction of new therapies that are safer and more effective, compared to currently available therapies… The U.S. Migraine Population with CV Risk Factors (2015-2022E) In 2015, nearly ..% or .. million patients of the total migraine patients in the U.S. had cardiovascular risk factors. Triptans were contraindicated in approximately ..%, or .. million patients. In addition, another ..% of the migraine patients were at a risk for silent myocardial ischemia for the given year.
n ilo M
Among the treated adult migraine patients in the U.S., nearly ..% patients received Triptans during 2014. Of the ..% Triptans treated population nearly ..% were treated from Triptans only, ..% from combination of Triptans & Prophylaxis and ..% with Triptans & other acute classes.
2015
2016E
2017E
2018E
High Risk
2019E
2020E
2021E
The prescription volume for acute migraine in the U.S. reached … million in the year 2015, with as estimation of reaching … million prescriptions by the end of year 2025.
2022E
Low Risk
The U.S. Acute Migraine Treated Population by Drug Type (2014)
t p c s re P n ilo M
The U.S. Acute Migraine Prescription Volume (2015-2025E)
Prophylaxis Only
Non- Triptan Treated
Triptan Only
Triptan & Prophylaxis
Triptan & Other Acute Classes
Contact Us:Details View Report These are abridged and sanitized sample pages from the comprehensive report on the “ Global Migraine Market �. To know more about this report or for any customized research requirement, please contact the following:
Koncept Analytics
Vikas Gupta BD Manager
CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T. +91-120-4130959 C: +91-9811715635 vikas@konceptanalytics.com
www.konceptanalytics.com